S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

argenx Stock Forecast, Price & News

-0.81 (-0.29%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
186,721 shs
Average Volume
176,252 shs
Market Capitalization
$14.22 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

argenx logo

About argenx

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$41.60 million
Book Value
$32.92 per share


Net Income
$-604.19 million
Pretax Margin




Free Float
Market Cap
$14.22 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.95 out of 5 stars

Medical Sector

668th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

102nd out of 201 stocks

Analyst Opinion: 4.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

argenx (NASDAQ:ARGX) Frequently Asked Questions

Is argenx a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 5 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" argenx stock.
View analyst ratings for argenx
or view top-rated stocks.

How has argenx's stock price been impacted by COVID-19 (Coronavirus)?

argenx's stock was trading at $133.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARGX stock has increased by 106.3% and is now trading at $276.10.
View which stocks have been most impacted by COVID-19

Are investors shorting argenx?

argenx saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,000,000 shares, an increase of 32.7% from the October 31st total of 753,400 shares. Based on an average daily volume of 179,300 shares, the days-to-cover ratio is currently 5.6 days. Approximately 2.0% of the shares of the stock are short sold.
View argenx's Short Interest

When is argenx's next earnings date?

argenx is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for argenx

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings data on Wednesday, October, 27th. The company reported ($4.10) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($4.48) by $0.38. argenx had a negative net margin of 73.28% and a negative trailing twelve-month return on equity of 24.48%. During the same period in the prior year, the business earned ($3.96) EPS.
View argenx's earnings history

What price target have analysts set for ARGX?

17 brokerages have issued 1 year target prices for argenx's shares. Their forecasts range from $250.00 to $430.00. On average, they anticipate argenx's stock price to reach $352.80 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price.
View analysts' price targets for argenx
or view top-rated stocks among Wall Street analysts.

Who are argenx's key executives?

argenx's management team includes the following people:
  • Tim van Hauwermeiren, Chief Executive Officer & Executive Director
  • R. Keith Woods, Chief Operating Officer
  • Karl Gubitz, Chief Financial Officer
  • Hans J. W. de Haard, Chief Scientific Officer
  • Wim Parys, Chief Medical Officer

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by many different institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (5.57%), Bellevue Group AG (1.91%), Jennison Associates LLC (1.62%), BlackRock Inc. (1.48%), Wellington Management Group LLP (1.30%) and Capital World Investors (1.28%).

Which major investors are selling argenx stock?

ARGX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, American Century Companies Inc., Artisan Partners Limited Partnership, Caption Management LLC, ArrowMark Colorado Holdings LLC, Thrivent Financial for Lutherans, TimesSquare Capital Management LLC, and Eaton Vance Management.

Which major investors are buying argenx stock?

ARGX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., Wellington Management Group LLP, RTW Investments LP, Jennison Associates LLC, Artal Group S.A., Caas Capital Management LP, and Janus Henderson Group PLC.

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $276.10.

How much money does argenx make?

argenx has a market capitalization of $14.22 billion and generates $41.60 million in revenue each year. The company earns $-604.19 million in net income (profit) each year or ($7.43) on an earnings per share basis.

How many employees does argenx have?

argenx employs 336 workers across the globe.

What is argenx's official website?

The official website for argenx is www.argenx.com.

Where are argenx's headquarters?

argenx is headquartered at Willemstraat 5, Breda P7, 4811 AH.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at (176) 303-0488 or via email at [email protected].

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.